At Serucell, we have developed a versatile and powerful therapeutic serum platform with applications in the dermatology field and potential pharmaceutical products in the field of regenerative medicine. Our proprietary platform, including patented processes, for single cell culture or co-culturing of any proliferative cells including mesenchymal stem cells has multiple potential applications including but not limited to; support media for cell implantation, cell growth or cell recovery in stem cell therapy, delivery media for cell therapies or bio compatible materials, in support of host tissue implantation (transplant), topical and injectable protein for therapeutics, scar “keloid” reduction & wound healing, and aesthetic - skincare products and pre & post procedure enhancement for dermatological procedures (chemical peel, micro needling, etc.).
KFS® (Keratinocyte Fibroblast Serum) Level 3 is our company’s first commercial skincare product launched in 2018 and is the only dual cell serum on the market. Serucell’s patented cellular manufacturing methods harness the innate signaling power of the body’s own cells to capture the bioactive potential of more than 1,500 molecules and building blocks that support the skin’s natural regeneration process. The Department of Plastic Surgery at WVU School of Medicine is currently initiating human POC studies in scar reduction using Serucell’s KFS Serum.